Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
16.58
+0.16 (0.98%)
Nov 5, 2024, 1:19 PM EST - Market open
Tyra Biosciences Employees
Tyra Biosciences had 49 employees as of December 31, 2023. The number of employees increased by 11 or 28.95% compared to the previous year.
Employees
49
Change (1Y)
11
Growth (1Y)
28.95%
Revenue / Employee
n/a
Profits / Employee
-$1,662,061
Market Cap
875.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 49 | 11 | 28.95% |
| Dec 31, 2022 | 38 | 13 | 52.00% |
| Dec 31, 2021 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aveanna Healthcare Holdings | 33,500 |
| Embecta | 2,200 |
| HealthStream | 1,092 |
| Bioventus | 970 |
| Cronos Group | 356 |
| Pliant Therapeutics | 158 |
| Silence Therapeutics | 109 |
| Capricor Therapeutics | 102 |
TYRA News
- 8 days ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PRNewsWire
- 11 days ago - Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
- 11 days ago - Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PRNewsWire
- 12 days ago - Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - PRNewsWire
- 15 days ago - Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point - Seeking Alpha
- 17 days ago - BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug - Benzinga
- 18 days ago - This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
- 25 days ago - Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) - PRNewsWire